AstraZeneca's lung cancer drug trial failure leads to 5% share dip and FDA approval doubts.
AstraZeneca's shares fell 5% to 121.10 pounds following disappointing trial results for its lung cancer drug, datopotamab deruxtecan. The drug, intended for advanced nonsquamous non-small cell lung cancer, failed to show significant improvement in overall survival rates. This setback raises doubts about its potential approval by the U.S. Food & Drug Administration and affects the FTSE 1000 index.
September 10, 2024
20 Articles